The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Sponsor

Alliance for Clinical Trials in Oncology (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06115499

Collaborator

National Cancer Institute (NCI) (NIH)

100

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Acinar Cell Carcinoma Pancreatic Adenocarcinoma Pancreatic Adenosquamous Carcinoma Pancreatic Carcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Squamous Cell Carcinoma Stage IV Pancreatic Cancer AJCC v8	Drug: Nab paclitaxel Drug: Gemcitabine Drug: Cisplatin Procedure: Magnetic Resonance Imaging Procedure: Computed Tomography Procedure: Biospecimen Collection	Phase 2/Phase 3

Detailed Description

PRIMARY OBJECTIVES:

To evaluate and compare overall response rate (ORR) in patients with BRCA1/2 or PALB2 mutant pancreas cancer whose disease has progressed on front-line fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX) treated with nab-paclitaxel, gemcitabine, and cisplatin (NABPLAGEM) = nab-paclitaxel, gemcitabine, and cisplatin (arm 1) versus nab-paclitaxel and gemcitabine (arm 2). (Phase II) II. To evaluate and compare overall survival (OS) time in patients with BRCA1/2 or PALB2 mutant whose disease has progressed on front-line FOLFIRINOX treated with 1) NABPLAGEM = nab-paclitaxel, gemcitabine, and cisplatin (arm 1) versus nab-paclitaxel and gemcitabine (arm 2). (Phase III)

SECONDARY OBJECTIVES:

To evaluate and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria between 2 treatment arms.
To evaluate and compare duration of response (DoR) between 2 treatment arms.
To evaluate and compare CA19-9 response (defined as patients with a baseline CA19-9 >= 2x upper limit of normal (ULN) who demonstrate a minimum 25% decrease in CA19-9 at any time point) between 2 treatment arms.
To evaluate and compare toxicity profile as assessed by treating clinicians between 2 treatment arms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive nab-paclitaxel intravenously (IV) over 30-40 minutes, gemcitabine IV over 30-40 minutes, and cisplatin IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo magnetic resonance imaging (MRI) or computed tomography (CT) throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.

ARM II: Patients receive nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30-40 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.

After completion of study treatment, patients are followed up within 30 days and then every 3 months for 2 years or until death, whichever comes first.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Anticipated Study Start Date :

Apr 9, 2024

Anticipated Primary Completion Date :

Jan 15, 2029

Anticipated Study Completion Date :

Dec 9, 2029

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm I (nab-paclitaxel, gemcitabine, cisplatin) Patients receive nab-paclitaxel IV over 30-40 minutes, gemcitabine IV over 30-40 minutes, and cisplatin IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.	Drug: Nab paclitaxel Given IV Other Names: ABI-007 Abraxane Albumin-bound Paclitaxel Protein-bound Paclitaxel Drug: Gemcitabine Given IV Drug: Cisplatin Given IV Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: MRI Procedure: Computed Tomography Undergo CT Other Names: CAT Scan CT Scan Procedure: Biospecimen Collection Undergo blood sample collection
Active Comparator: Arm II (nab-paclitaxel, gemcitabine) Patients receive nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30-40 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.	Drug: Nab paclitaxel Given IV Other Names: ABI-007 Abraxane Albumin-bound Paclitaxel Protein-bound Paclitaxel Drug: Gemcitabine Given IV Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: MRI Procedure: Computed Tomography Undergo CT Other Names: CAT Scan CT Scan Procedure: Biospecimen Collection Undergo blood sample collection

Arm

Intervention/Treatment

Experimental: Arm I (nab-paclitaxel, gemcitabine, cisplatin)

Patients receive nab-paclitaxel IV over 30-40 minutes, gemcitabine IV over 30-40 minutes, and cisplatin IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.

Drug: Nab paclitaxel

Given IV

Other Names:

ABI-007

Abraxane

Albumin-bound Paclitaxel

Protein-bound Paclitaxel

Drug: Gemcitabine

Given IV

Drug: Cisplatin

Given IV

Procedure: Magnetic Resonance Imaging

Undergo MRI

Other Names:

MRI

Procedure: Computed Tomography

Undergo CT

Other Names:

CAT Scan

CT Scan

Procedure: Biospecimen Collection

Undergo blood sample collection

Active Comparator: Arm II (nab-paclitaxel, gemcitabine)

Patients receive nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30-40 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.

Drug: Nab paclitaxel

Given IV

Other Names:

ABI-007

Abraxane

Albumin-bound Paclitaxel

Protein-bound Paclitaxel

Drug: Gemcitabine

Given IV

Procedure: Magnetic Resonance Imaging

Undergo MRI

Other Names:

MRI

Procedure: Computed Tomography

Undergo CT

Other Names:

CAT Scan

CT Scan

Procedure: Biospecimen Collection

Undergo blood sample collection

Outcome Measures

Primary Outcome Measures

Overall response rate (ORR) (Phase II) [Up to 12 months]
Will be assessed by the proportion of patients who achieve complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) during the protocol treatment. Fisher's exact test will be conducted based on the first 32 patients in each arm who meet PP population criteria.
Overall Survival (OS) (Phase III) [From the date of randomization to the date of death due to all causes, assessed up to 5 years]
Will be conducted on modified intention-to-treat population. Stratified Cox model will be constructed to compare OS in the experimental arm to OS in the control arm.

Secondary Outcome Measures

Progression-free survival [From the date of randomization to the date of first documented disease progression or death due to all causes, whichever occurs first, assessed up to 5 years]
Will be assessed per RECIST 1.1. Will be estimated, in each arm, using the method of Kaplan-Meier and compared by stratified Cox regression model.
Incidence of adverse events [Up to 30 days after the last dose of study treatment]
The maximum grade for each type of adverse events that are possibly, probably, or definitely related to study treatments will be recorded for each patient.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Metastatic pancreatic adenocarcinoma. Adenosquamous carcinoma, squamous carcinoma, acinar cell carcinoma, and carcinoma not otherwise specified are also acceptable
BRCA1/2 or PALB2 mutation (somatic or germline) identified on any Clinical Laboratory Improvement Amendments (CLIA)-certified gene panel. Mutations must be considered pathogenic or likely pathogenic by a reference database such as ClinVar or OncoKb.org. (Submission of mutation report will be required)
Measurable disease
Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment
Clinical or radiographic progression on first-line FOLFIRINOX (or nanoliposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin [NALIRIFOX]) for metastatic disease
Patients whose front-line chemotherapy was required to be simplified due to toxicity associated with any of the constituent components of FOLFIRINOX/NALIRIFOX (e.g. simplified to leucovorin calcium, fluorouracil, and oxaliplatin [FOLFOX], leucovorin calcium, fluorouracil, and irinotecan [FOLFIRI], fluorouracil [5-FU] [including capecitabine]) will be eligible
Patients with progressive disease while on maintenance PARP inhibitor treatment after FOLFIRINOX (or NALIRIFOX), irrespective of how long ago they received FOLFIRINOX/NALIRIFOX, will also be eligible
Patients who develop metastatic disease during or within 6 months after completing FOLFIRINOX/NALIRIFOX in either the locally advanced or adjuvant/neoadjuvant settings will be eligible
Patients may not have received prior cisplatin for their pancreatic cancer in any setting

Note: Patients may have previously received gemcitabine +/- nab-paclitaxel for resectable (neoadjuvant/adjuvant) or locally advanced disease if (1) treatment was completed > 1 year ago and (2) in the opinion of the treating provider, re-treatment with gemcitabine/nab-paclitaxel is appropriate

Age >= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky performance status >= 60)
Absolute neutrophil count >= 1,500/mm^3
Platelet count >= 100,000/mm^3
Hemoglobin >= 8.0 g/dL
Creatinine =< 1.8 x institutional upper limit of normal (ULN) or calculated creatinine clearance (Calc. CrCl) > 40 mL/min
Total bilirubin =< 2.0 x institutional ULN

Any elevated bilirubin should be asymptomatic at enrollment (except for participants with documented Gilbert's syndrome who may only be included if the total bilirubin =< 3 x ULN or direct bilirubin =< 1.5 x ULN)

Aspartate transaminase (AST)/alanine transaminase (ALT) =< 3 x institutional ULN

AST/ALT of =< 5 x ULN if liver metastases are present

Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects

Therefore, for women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required

Patients with > grade 2 peripheral sensory neuropathy are not eligible
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for at least 8-weeks.

Patients with known, new or progressive brain metastases (active brain metastases) or leptomeningeal disease are ineligible

Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load anytime within 6 months prior to registration are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Concomitant chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study
Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment